Ultrasound Flowchart Outperforms CT in Stomach Cancer Staging Study

Gastric cancer remains one of the world’s most lethal malignancies, and one of the most stubborn technical challenges in treating it has been a deceptively simple question: how deep has the tumor grown into the stomach wall? The answer, captured in what oncologists call T staging, determines whether a patient receives endoscopic resection, neoadjuvant chemotherapy, or immediate radical surgery. Now a prospective study from Peking University Cancer Hospital and Institute reports that a carefully standardized ultrasound technique, enhanced by an oral contrast agent, can answer that question with accuracy that matches or exceeds contrast-enhanced computed tomography, the workhorse imaging modality used in most cancer centers today. The findings, published in BMC Cancer, suggest that a low-cost, radiation-free bedside technique could earn a far more prominent role in the preoperative workup of stomach cancer.

The technique at the center of the study is oral contrast-enhanced transabdominal ultrasound, abbreviated OCTU. Conventional transabdominal ultrasound of the stomach has long been hampered by a fundamental physics problem: air in the gastric lumen reflects sound waves almost completely, obscuring the wall beneath. By asking patients to swallow an oral contrast agent that fills and distends the stomach, the examiners eliminate the air barrier and create an acoustic window through which the layered architecture of the gastric wall becomes visible. Under these conditions, the normal stomach wall resolves into five distinct echogenic bands, labeled L1 through L5, corresponding histologically to the mucosal surface, the deep mucosa, the submucosa, the muscularis propria, and the serosa. Tumor depth can then be judged by observing which of these layers a lesion has thickened, disrupted, or breached.

What has limited OCTU in practice is subjectivity. Different ultrasonographers, looking at the same five-layer pattern, have historically disagreed about whether a tumor is confined to the submucosa or has invaded the muscle layer. The Beijing team, led by Yu-Hui Liu, He-Wen Tang, Kun Yan, and Ying Dai, set out to replace impression with measurement. Between December 2023 and December 2024, they prospectively enrolled 150 patients with histologically confirmed gastric cancer who underwent OCTU followed by surgical resection, allowing the ultrasound findings to be checked against the gold standard of pathology. The cohort was divided into a training set of 116 patients, used to derive diagnostic thresholds, and an independent testing set of 34 patients, used to validate them. Two blinded ultrasonographers independently reviewed all images, and the study itself was registered with the Chinese Clinical Trial Registry before enrollment began.

The first practical question was whether the technique could even see the tumors. OCTU visualized the lesion in 144 of the 150 patients, a 96 percent detection rate. The six failures were instructive: five were T1a tumors, the earliest category, in which cancer remains confined to the superficial mucosa, and one was a T1b tumor. In other words, the technique rarely misses clinically significant disease, but very shallow lesions can escape detection, a limitation the authors acknowledge openly. Among the 104 men and 46 women enrolled, whose mean age was 60.5 years, the vast majority of tumors were amenable to layer-by-layer analysis.

The heart of the study lies in its quantitative approach to the five layers. Rather than simply eyeballing whether a layer looked interrupted, the ultrasonographers measured the thickness of each layer at the tumor site and compared it with the thickness of the same layer in adjacent normal wall, yielding a thickness difference for each band. Receiver operating characteristic analysis in the training set then identified cutoff values that separated one T stage from the next. The submucosa, layer L3, proved to be the pivotal structure. A difference in L3 thickness of 0.11 centimeters separated T1a from T1b tumors with an area under the curve of 0.957, while a cutoff of 0.23 centimeters distinguished T1b from T2 with an area under the curve of 0.910. These are strikingly high discriminative values for a bedside imaging measurement.

The algorithm then proceeds stepwise down the wall. When the L3 measurement places a tumor in the T2 range, a difference in L4 thickness, the muscularis propria, of 0.24 centimeters or more, with an area under the curve of 0.860, signals progression to T3. Interruption of the L3 layer itself, meaning a visible break in the submucosal echo band, narrows the diagnostic range to T2 or T3, excluding earlier stages. Finally, protrusion of the tumor beyond the serosal line, layer L5, by more than 0.50 centimeters identifies T4 disease, where the cancer has grown through the stomach wall, with an area under the curve of 0.980. Assembled into a diagnostic flowchart, these four objective indicators allow any trained ultrasonographer to walk from measurement to stage in a reproducible sequence, rather than relying on gestalt.

Validation results were competitive. In the combined analysis, the flowchart achieved 78.4 percent overall T-staging accuracy, and 76.5 percent in the independent testing set. Contrast-enhanced CT, performed on the same patients, managed only 66.4 percent, a difference that was statistically significant. The advantage was concentrated precisely where it matters most clinically: early gastric cancer. For distinguishing T1a from T1b disease, OCTU reached 65.2 percent accuracy against 39.1 percent for CT, and for separating T1 from T2 tumors it scored 72.0 percent versus 48.0 percent, both differences significant. For advanced tumors, T3 and T4, the two modalities performed comparably. Because the choice between endoscopic resection and major surgery hinges on whether an early tumor has reached the submucosa, this superiority in early-stage discrimination carries direct surgical consequences.

The comparison with endoscopic ultrasonography, the current reference standard for depth assessment, is an important context for these numbers. EUS places a high-frequency transducer directly inside the stomach and offers excellent layer resolution, but it is invasive, operator-dependent, expensive, and unavailable in many centers, particularly in regions where gastric cancer is most prevalent. OCTU, by contrast, requires only a standard ultrasound machine, an oral contrast agent, and a trained sonographer. It involves no ionizing radiation, no sedation, and no endoscopic instrumentation. A validated, standardized OCTU protocol could therefore extend accurate depth staging to hospitals that will never have the endoscopic ultrasound volume to develop expertise, and could serve as a rapid triage tool even in well-equipped centers.

The study’s limitations are those of a single-center design. All patients were imaged at one high-volume cancer hospital in Beijing by sonographers embedded in a specialized oncology practice, and the testing set of 34 patients, while adequate for validation, is modest. Whether the reported cutoffs of 0.11, 0.23, 0.24, and 0.50 centimeters transfer unchanged to other machines, other contrast agents, and less specialized operators will require multicenter confirmation. The six missed early tumors also mean OCTU cannot stand entirely alone; endoscopy remains indispensable for detecting and characterizing the primary lesion. What the study demonstrates is that, once a tumor is identified, its depth can be staged objectively and reproducibly from the body surface.

Still, the implications are considerable. Gastr cancer incidence remains high across East Asia and rising in many other regions, and every patient with resectable disease faces a staging pathway that shapes treatment. A technique that is cheaper than CT, safer than repeated radiation exposure, more accurate than CT for the early stages that determine surgical strategy, and now supported by an explicit, measurement-based flowchart rather than subjective reading, represents a meaningful shift in what routine preoperative assessment can look like. The Beijing team’s work, funded by the Beijing Natural Science Foundation, provides the kind of prospectively validated, threshold-driven protocol that imaging guidelines demand, and it arrives with a clear roadmap: multicenter trials to confirm generalizability, and integration of OCTU into staging algorithms alongside endoscopy and CT. If those steps succeed, the humble ultrasound probe, armed with a swallow of oral contrast and a set of millimeter-scale cutoffs, may become a standard first stop in deciding how a stomach cancer is treated.

Subject of Research: Preoperative T-staging of gastric cancer using oral contrast-enhanced transabdominal ultrasound

Article Title: Preoperative T-staging flowchart using oral contrast-enhanced transabdominal ultrasound for gastric cancer: single-center prospective study

Article References: Liu, Y.-H., Tang, H.-W., Wu, A.-W., Shan, F., Li, S., Yan, K., & Dai, Y. (2026). Preoperative T-staging flowchart using oral contrast-enhanced transabdominal ultrasound for gastric cancer: single-center prospective study. BMC Cancer. https://doi.org/10.1186/s12885-026-17016-9

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17016-9

Keywords: gastric cancer, T staging, oral contrast-enhanced ultrasound, transabdominal ultrasound, contrast-enhanced CT, cancer imaging, neoplasm staging, gastric wall layers, prospective study, diagnostic flowchart, early gastric cancer, Peking University Cancer Hospital